½ÃÀ庸°í¼­
»óǰÄÚµå
1542879

¼¼°èÀÇ Á᫐ Á¤¸Æ ¾×¼¼½º µð¹ÙÀ̽º ½ÃÀå(2024-2031³â)

Global Central Vascular Access Devices Market - 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DataM Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 181 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

°³¿ä

¼¼°èÀÇ Á᫐ Á¤¸Æ ¾×¼¼½º µð¹ÙÀ̽º ½ÃÀåÀº 2023³â¿¡ 17¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2031³â¿¡´Â 28¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2024-2031³â CAGRÀº 6.2%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

Á᫐ Á¤¸Æ ¾×¼¼½º µð¹ÙÀ̽º(CVAD)´Â Á¤¸Æ³» Ä¡·á, Ç÷¾× »ùÇà äÃë ¹× ±âŸ Áß¿äÇÑ ÀÇ·á ÀýÂ÷¸¦ ¼öÇàÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÈ Ư¼ö ÀÇ·á±â±âÀÔ´Ï´Ù.

Áß½ÉÁ¤¸ÆÁ¢±ÙÀåºñ(CVAD)´Â Á¤¸ÆÁ¢±ÙÆ÷Æ® ¶Ç´Â Ä«Å×ÅͶó°íµµ Çϸç, Ç÷·ù¿¡ ÀÚÁÖ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï ȯÀÚÀÇ ±½Àº Á¤¸Æ¿¡ ¼³Ä¡µÇ´Â °¡´Ã°í ¼ÓÀÌ ºó Ç÷º¼­ºí Æ©ºêÀÔ´Ï´Ù. ÀÌ ±â±¸´Â ¿Ü°ú ÀÇ»ç ¶Ç´Â ÁßÀçÀû ¹æ»ç¼± Àü¹®Àǰ¡ Àü½Å ¸¶Ãë À¯¹«¿¡ °ü°è¾øÀÌ »ðÀÔÇÕ´Ï´Ù.

CVAD´Â ƯÈ÷ È­Çпä¹ý, Ç×»ýÁ¦ Àå±â Åõ¿©, Àü½Åºñ°æ±¸¿µ¾ç¿ä¹ý µîÀÇ Ä¡·á¸¦ ¹Þ´Â ȯÀڵ鿡°Ô Çö´ë ÀÇ·á¿¡ ÀÖÀ¸¸ç, ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Àåºñ´Â Àå±â°£ Á¦ÀÚ¸®¿¡ À¯ÁöµÇµµ·Ï ¼³°èµÇ¾úÀ¸¹Ç·Î ¼øÈ¯°è¿¡ ÀÚÁÖ Á¢±ÙÇØ¾ß Çϴ ȯÀÚ¿¡°Ô ÀûÇÕÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ :

ÃËÁø¿äÀÎ

¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ±â¼úÀÇ ¹ßÀü

¼¼°è Á᫐ Á¤¸Æ ¾×¼¼½º µð¹ÙÀ̽º ½ÃÀå ¼ö¿ä´Â ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ±â¼ú ¹ßÀüÀÔ´Ï´Ù.

½ÉÇ÷°ü Áúȯ(CVDs) ¹× ¸¸¼º ½ÅÀå Áúȯ(CKDs)À» Æ÷ÇÔÇÑ ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â Áß¾Ó Á¤¸Æ Á¢±Ù Àåºñ(CVADs)¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î, 2023³â 11¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ Á¶»ç º¸°í¼­¿¡ µû¸£¸é ¸¸¼º ½ÅÀå Áúȯ(CKD)Àº ´ç´¢º´(DM) ȯÀÚ¿¡°Ô ÀÚÁÖ ¹ß»ýÇϸç À̵é ȯÀÚÀÇ 40%°¡ ¾Î°í ÀÖ´Ù°íÇÕ´Ï´Ù, À̵é ȯÀÚÀÇ ¾à 40%°¡ ¾Î°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´ç´¢º´Àº ½ÉÇ÷°ü Áúȯ(CVD)ÀÇ Áß¿äÇÑ À§Çè ¿ä¼ÒÀ̸ç CKD´ÂÀÌ À§Çè ¿ä¼Ò¸¦ ¸Å°³ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

Àüµ¿½Ä ÁÖÀÔ½Ä Ä«Å×ÅÍ¿Í Ç×±Õ Ä«Å×ÅÍ °³¹ß µî Ç÷°ü Á¢±Ù ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÌ·¯ÇÑ ±â±âÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¿µ»ó °Ë»ç¿Í °°ÀÌ °í¾Ð ÁÖÀÔÀÌ ¼ö¹ÝµÇ´Â ½Ã¼ú¿¡ ƯÈ÷ Áß¿äÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌ ¾÷°èÀÇ ÁÖ¿ä ±â¾÷Àº ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ´Â Ç÷°ü Àåºñ ¿¬±¸¿Í ÆÄÆ®³Ê½Ê ¹× Çù¾÷¿¡ ´õ¿í ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 6¿ù Magenta MedicalÀº ¼¼°è¿¡¼­ °¡Àå ÀÛÀº ½ÉÀå ÆßÇÁ·Î ÀÎÁ¤¹Þ°í ÀÖ´Â Elevate °æÇÇÀû ÁÂ½É½Ç º¸Á¶ Àåºñ(LVAD)ÀÇ Á¶±â Ÿ´ç¼º ½ÃÇèÀ» ½ÃÀÛÇß½À´Ï´Ù.

ÀÌ ½ÃÇèÀº °íÀ§Çè °æÇÇÀû °ü»óµ¿¸Æ ÁßÀç¼ú(HR-PCI) ½Ã¼ú¿¡¼­ Ç÷°ü Á¢±Ù ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­ÇÏ´Â µ¥ ÀÖÀ¸¸ç, ÀÌ ÀåºñÀÇ È¿°ú¸¦ Æò°¡ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¿¤¸®º£ÀÌÅÍ ÆßÇÁ´Â ÀϽÃÀûÀÎ ±â°èÀû ¼øÈ¯ º¸Á¶¸¦ Á¦°øÇϵµ·Ï ¼³°èµÇ¾î ÀÌ·¯ÇÑ Áß¿äÇÑ ÁßÀç½Ã¼ú Áß È¯ÀÚÀÇ ¾ÈÀü°ú °á°ú¸¦ °³¼±ÇÕ´Ï´Ù. ¼ÒÇü »ðÀÔ ÇÁ·ÎÆÄÀÏÀ» »ç¿ëÇÔÀ¸·Î½á ÀϹÝÀûÀ¸·Î ħ½ÀÀûÀÎ ½Ã¼úÀÌ ÇÊ¿äÇÑ ±âÁ¸ÀÇ ´ëÇü ÆßÇÁ¿Í °ü·ÃµÈ À§ÇèÀ» ÁÙÀÌ·Á°í ÇÕ´Ï´Ù.

¶ÇÇÑ 2023³â 3¿ù ¹Ì±¹¿Ü°úÇÐȸ(ACS)¿Í ¹Ì±¹Ç÷°ü¿Ü°úÇÐȸ(SVS)´Â °øµ¿À¸·Î Ç÷°ü °ËÁõ ÇÁ·Î±×·¥(Vascular-VP)À» Ãâ¹üÇß½À´Ï´Ù. ÀÌ´Â ÀÔ¿ø ȯ°æ¿¡¼­ Ç÷°ü ¼ö¼ú ¹× ÁßÀçÀû Ä¡·á¸¦ ¹Þ´Â ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϰí ÃÖÀûÀÇ Ä¡·á¸¦ Á¦°øÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â Àü±¹ÀûÀΠǰÁú °ËÁõ ±¸»óÀÔ´Ï´Ù. ÀÌ Áõ°Å¿¡ ±â¹ÝÇÑ Ç¥ÁØÈ­µÈ ÇÁ·Î±×·¥Àº º´¿øÀÌ Ç÷°ü Ä¡·áÀÇ ÁúÀ» Çâ»ó½Ã۱â À§ÇÑ ÀÎÇÁ¶ó¸¦ ±¸ÃàÇÏ°í °­È­ÇÒ ¼ö ÀÖ´Â ÇÁ·¹ÀÓ¿öÅ©¸¦ Á¦°øÇÕ´Ï´Ù.

¾ïÁ¦¿äÀÎ

°¨¿° ¹× ÇÕº´Áõ À§Çè, CVAD ¼³Ä¡ ¹× Á¤ºñ¿¡ µå´Â ³ôÀº ºñ¿ë, Á¦Ç° ¸®ÄÝ ¹× °íÀå µîÀÇ ¿äÀÎÀÌ ½ÃÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼°è Á᫐ Á¤¸Æ ¾×¼¼½º µð¹ÙÀ̽º ½ÃÀåÀº À¯Çü, ¾ÖÇø®ÄÉÀ̼Ç, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

¾à¹° Åõ¿© ºÎ¹®Àº Àü ¼¼°è Á᫐ Á¤¸Æ ¾×¼¼½º µð¹ÙÀ̽º ½ÃÀå Á¡À¯À²ÀÇ ¾à 48.2%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

¾à¹° Åõ¿© ºÎ¹®Àº ¿¹Ãø ±â°£ Áß °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 2024³â 2¿ù ScienceDirectÀÇ Á¶»ç ¹ßÇ¥¿¡ µû¸£¸é Àü ¼¼°è¿¡¼­ ¾à 7¾ï-8¾ï ¸íÀÇ »ç¶÷µéÀÌ ¸¸¼º ½ÅÀå Áúȯ(CKD)°ú ¾ÏÀ» Æ÷ÇÔÇÑ ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ¾à¹° Åõ¿© ºÎ¹®À» À̲ô´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ƯÈ÷ ¸¸¼ºÁúȯ ȯÀÚÀÇ Àü½Å Ä¡·á¿¡ ÇʼöÀûÀÎ Á¤¸Æ ³»(IV) Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â ¾à¹° Åõ¿©, Ç÷¾× ÃßÃâ, ¼ö¾× ÁÖÀÔ µî ´Ù¾çÇÑ ¸ñÀûÀ» ´Þ¼ºÇÒ ¼ö ÀÖÀ¸¸ç, ÀÓ»ó ȯ°æ¿¡¼­ ÀûÀÀ¼ºÀÌ ³ôÀº ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î °æÁ¤¸ÆÀ» ÅëÇØ ÁßÃß¿¡ »ðÀÔÇϰųª ÆÈÀÇ ¸»ÃÊ ºÎÀ§¿¡ »ðÀÔÇÏ´Â µî ȯÀÚÀÇ Æ¯Á¤ ¿ä±¸»çÇ׿¡ µû¶ó ´Ù¾çÇÑ ¹æ¹ýÀ¸·Î »ðÀÔÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¾÷°èÀÇ ÁÖ¿ä ¾÷üµéÀº ÀÌ ½ÃÀå ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Çõ½ÅÀûÀÎ Á¦Ç° Ãâ½Ã ¹× ±â¼ú °³¹ßÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 10¿ù B. Braun Medical Inc.´Â ¸ÖƼ ¾×¼¼½º Ç÷¾× Á¦¾î ±â´ÉÀ» °®Ãá »õ·Î¿î Introcan Safety 2 IV Ä«Å×Å͸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ÃֽŠÇõ½ÅÀº ¼öµ¿Àû ¹Ù´Ã Âñ¸² ¿¹¹æ¿¡ ´ëÇÑ B.BraunÀÇ ¾à¼ÓÀ» À̾´Â °ÍÀÔ´Ï´Ù. ÀÌ Ä«Å×ÅÍ´Â ¹Ù´Ã¿¡ Âñ¸®´Â ¼Õ»ó¿¡ ´ëÇÑ ÀÚµ¿ º¸È£ ±â´ÉÀ» Á¦°øÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Çãºê¿¡ Á¢±ÙÇÒ ¶§¸¶´Ù ÀÓ»óÀǰ¡ Ç÷¾×¿¡ ³ëÃâµÇÁö ¾Êµµ·Ï º¸È£ÇÏ´Â Ç÷¾× Á¦¾î ¸ÞÄ¿´ÏÁòÀ» °®Ãß°í ÀÖ½À´Ï´Ù. ÀÌ ±â´ÉÀº Á¤¸Æ ÁÖ»ç Áß Ç÷¾× À¯·¡ º´¿ø±Õ¿¡ ³ëÃâµÉ À§ÇèÀ» Å©°Ô ÁÙ¿©ÁÝ´Ï´Ù.

°°Àº ÇØ 12¿ù, B. ºê¶ó¿îÀº Çõ½ÅÀûÀÎ Äɾî»çÀÌÆ® ¸¶ÀÌÅ©·Î ·ç¾î ¾×¼¼½º Àåºñ¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ½ÅÁ¦Ç°Àº À¯ÇØÇÑ È­ÇÐ ¹°Áú¿¡ ´ëÇÑ ³ëÃâÀ» ÃÖ¼ÒÈ­ÇÏ°í °¨¿° À§ÇèÀ» ÁÙÀÓÀ¸·Î½á ȯÀÚ¿Í ÀÇ·á Àü¹®°¡ ¸ðµÎ¿¡°Ô Á¤¸Æ³» Á¢±ÙÀÇ ¾ÈÀü¼ºÀ» ³ôÀÌ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

½ÃÀå Áö¿ªº° Á¡À¯À²

¼¼°èÀÇ Á᫐ Á¤¸Æ ¾×¼¼½º µð¹ÙÀ̽º ½ÃÀå Á¡À¯À²Àº ºÏ¹Ì°¡ ¾à 43.4%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, ±â¼ú ¹ßÀü, °í·ÉÈ­, ÀÇ·á ½Ã¼³ È®´ë µîÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϸ鼭 ¿¹Ãø ±â°£ Áß °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ¸¹Àº ÁÖ¿ä ±â¾÷ÀÌ ÁøÃâÇϰí ÀÖ°í, ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖÀ¸¸ç, ´Ù¾çÇÑ Á¦Ç° Ãâ½Ã°¡ ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î BD´Â 2023³â 11¿ù¿¡ ¸»ÃÊ »ðÀÔÇü Áß½ÉÁ¤¸ÆÄ«Å×ÅÍ(PICC) ¹× Áß½ÉÁ¤¸ÆÄ«Å×Å͸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ Ç÷°ü Á¢±Ù Àåºñ¸¦ ¼³Ä¡ÇÒ ¶§ ÀÓ»óÀÇÀÇ È¿À²¼ºÀ» ³ôÀ̱â À§ÇØ °í¾ÈµÈ Sightlight 9 ÃÊÀ½ÆÄ ½Ã½ºÅÛÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Ã·´Ü ½Ã½ºÅÛÀº »ç¿ëÇϱ⠽¬¿î 15.6ÀÎÄ¡ ÅÍÄ¡½ºÅ©¸°°ú ¶Ù¾î³­ È­ÁúÀ» Ư¡À¸·Î Çϸç, ¼º°øÀûÀÎ Ä«Å×ÅÍ »ðÀÔÀ» À§ÇÑ ÇʼöÀûÀÎ ÅøÀ» Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ 2022³â 3¿ù, Shockwave MedicalÀº Shockwave M5 ¸»ÃÊÇ÷°ü³» °á¼®ÆÄ¼â(IVL) Ä«Å×ÅͰ¡ CE ¸¶Å©¿Í FDA ½ÂÀÎÀ» ȹµæÇϰí Àü ¼¼°è¿¡¼­ Ãâ½ÃµÉ °ÍÀ̶ó°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Ä«Å×ÅÍ´Â IVL Ä¡·áÀÇ Ä¡·á ½Ã°£À» ´ÜÃàÇϰí, ¶Ç ´Ù¸¥ Á¢±Ù ¿É¼ÇÀ» Á¦°øÇϸç, ´õ Å« Ç÷°ü Å©±âÀÇ È¯ÀÚ¿¡°Ôµµ IVL Ä¡·á¸¦ È®´ëÇÒ ¼ö ÀÖµµ·Ï Ưº°È÷ °í¾ÈµÈ Ä«Å×ÅÍ·Î, Shockwave M5 Ä«Å×ÅÍÀÇ Ãâ½Ã´Â ½ÉÇÏ°Ô ¼®È¸È­µÈ ½ÉÇ÷°ü Áúȯ Ä¡·á¿¡ ÀÖÀ¸¸ç, Å« ÁøÀüÀÔ´Ï´Ù. Ç÷°ü ÁßÀç½Ã¼úÀÇ È¿À²¼º°ú È¿°ú¸¦ Çâ»ó½Ãų ¼ö Àִ ȹ±âÀûÀÎ ¹ßÀüÀÔ´Ï´Ù.

¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü°ú Á¦Ç° ½ÂÀÎÀÌ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 11¿ù BD´Â FDA 510(k) ½ÂÀÎÀ» ¹ÞÀº »õ·Î¿î PIVOTM Pro ¹«Ä§ äÇ÷ Àåºñ(PIVOTM Pro needle-free blood sampling device)¸¦ ¹ßÇ¥Çß½À´Ï´Ù. Access¸¦ Æ÷ÇÔÇÑ ÀÏüÇü ¹× ±ä ±æÀÌÀÇ ¸»ÃÊÁ¤¸Æ Ä«Å×ÅÍ¿Í ÇÔ²² »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¸¸¼ºÁúȯÀÇ Áõ°¡¿Í ±â¼úÀÇ Áøº¸
    • ¾ïÁ¦¿äÀÎ
      • °¨¿°Áõ°ú ÇÕº´ÁõÀÇ ¸®½ºÅ©
    • ±âȸ
    • ¿µÇ⠺м®

Á¦5Àå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ºÐ¼®
  • °ø±Þ¸Á ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ±ÔÁ¦ ºÐ¼®

Á¦6Àå À¯Çüº°

  • ¸»ÃÊ »ðÀÔÇü Á᫐ Á¤¸Æ Ä«Å×ÅÍ
  • ºñÅͳÎÇü Ä«Å×ÅÍ
  • ÅͳÎÇü Ä«Å×ÅÍ
  • À̽ÄÇü Æ÷Æ®

Á¦7Àå ¿ëµµº°

  • ¾àÁ¦ Åõ¿©
  • ºñ°æ±¸ ¿µ¾ç
  • È­Çпä¹ý
  • ¼öÇ÷
  • Áø´Ü°ú °Ë»ç

Á¦8Àå ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Àü¹® Ŭ¸®´Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦9Àå Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ³²¹Ì
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • °æÀï ½Ã³ª¸®¿À
  • ½ÃÀå ÇöȲ/Á¡À¯À² ºÐ¼®
  • M&A ºÐ¼®

Á¦11Àå ±â¾÷ °³¿ä

  • B. Braun SE
    • ȸ»ç °³¿ä
    • Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í ¼³¸í
    • À繫 °³¿ä
    • ÁÖ¿ä ¹ßÀü
  • Terumo Medical Corporation
  • Teleflex Incorporated
  • Access Vascular, Inc.
  • BD
  • Cook
  • Medtronic
  • Baxter
  • Smith's Group plc(ICU Medical, Inc.)
  • AngioDynamics(*LIST NOT EXHAUSTIVE)

Á¦12Àå ºÎ·Ï

KSA 24.09.06

Overview

The Global Central Vascular Access Devices Market reached US$ 1.74 billion in 2023 and is expected to reach US$ 2.82 billion by 2031 growing with a CAGR of 6.2% during the forecast period 2024-2031.

Central vascular access devices (CVADs) are specialized medical tools designed to enable the delivery of intravenous treatments, collection of blood samples, and performance of other essential medical procedures.

Central venous access devices (CVAD), also referred to as venous access ports or catheters are thin, hollow, flexible tubes placed in large veins of patients to allow frequent access to threads in the bloodstream. These devices are inserted either by surgeons or interventional radiologists with or without the use of general anesthesia.

CVADs are essential in contemporary healthcare, especially for individuals receiving treatments like chemotherapy, prolonged antibiotic therapy, and total parenteral nutrition. These devices are engineered to stay in place for prolonged durations, making them well-suited for patients who need frequent access to their circulatory system.

Market Dynamics: Drivers

Rising prevalence of chronic diseases & technological advancements

The demand for the global central vascular access devices market is driven by multiple factors. One of the primary factors is the rising prevalence of chronic diseases & technological advancements.

The growing prevalence of chronic illnesses, including cardiovascular diseases (CVDs) and chronic kidney disease (CKD), is a major factor fueling the demand for central vascular access devices (CVADs). According to an NCBI research publication in November 2023, chronic kidney disease (CKD) frequently occurs in individuals with diabetes mellitus (DM), affecting about 40% of these patients. Additionally, DM serves as a significant risk factor for cardiovascular disease (CVD), with CKD playing a crucial role in mediating this risk.

Advancements in vascular access technology, including the creation of power-injectable and antimicrobial catheters, are improving the safety and effectiveness of these devices. These innovations are particularly important for procedures that involve high-pressure injections, like imaging studies.

Moreover, key players in the industry more focus on research studies in vascular devices and partnerships & collaborations that would drive this market growth. For instance, in June 2023, Magenta Medical initiated an early feasibility study for its Elevate Percutaneous Left Ventricular Assist Device (pLVAD), recognized as the world's smallest heart pump.

This study aims to assess the device's effectiveness in minimizing vascular access complications during high-risk percutaneous coronary intervention (HR-PCI) procedures. The Elevate pump is designed to provide temporary mechanical circulatory support, enhancing patient safety and outcomes during these critical interventions. By using a smaller insertion profile, the device seeks to reduce the risks associated with traditional larger pumps that typically require more invasive procedures.

Similarly, in March 2023, the American College of Surgeons (ACS) and the Society for Vascular Surgery (SVS) collaborated to launch the Vascular Verification Program (Vascular-VP), a national quality verification initiative aimed at improving outcomes and delivering optimal care for patients receiving vascular surgical and interventional treatment in inpatient settings. This evidence-driven, standardized program provides a framework for hospitals to establish and enhance their vascular care quality improvement infrastructure.

Restraints

Factors such as the risk of infections & complications, high costs involved in the placement and maintenance of CVADs, and product recalls and failures are expected to hamper the market.

Market Segment Analysis

The global central vascular access devices market is segmented based on type, application, end-user, and region.

The drug administration segment accounted for approximately 48.2% of the global central vascular access devices market share

The drug administration segment is expected to hold the largest market share over the forecast period. The growing prevalence of chronic illnesses, including chronic kidney disease (CKD) and cancer, is a key factor propelling the drug administration segment. As per ScienceDirect research publication in February 2024, around 700-800 million individuals worldwide suffer from CKD, driving the demand for central vascular access devices market.

The expansion of this segment is primarily fueled by the increasing need for intravenous (IV) therapies, which are crucial for delivering systemic treatments, particularly for patients with chronic illnesses. These devices serve multiple purposes, including drug administration, blood extraction, and fluid delivery, which makes them adaptable tools in clinical environments. They can be inserted centrally, for example, via the jugular vein, or peripherally in the arm, based on the specific requirements of the patient.

Moreover, key players in the industry have innovative product launches and technological developments that would drive this segment's growth in this market. For instance, in October 2023, B. Braun Medical Inc. unveiled its new Introcan Safety 2 IV Catheter featuring Multi-Access Blood Control. This latest innovation continues B. Braun's commitment to passive needlestick prevention. The catheter not only provides automatic protection against needlestick injuries but also includes a blood control mechanism that safeguards clinicians from blood exposure each time the hub is accessed. This feature significantly reduces the risk of exposure to bloodborne pathogens during the intravenous (IV) process.

Similarly, in December 2023, B. Braun unveiled its innovative CARESITE Micro Luer Access Device. This new product aims to enhance the safety of intravenous (IV) access for both patients and healthcare professionals by minimizing exposure to harmful chemicals and reducing the risk of infection.

Market Geographical Share

North America accounted for approximately 43.4% of the global central vascular access devices market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of chronic diseases, technological advancements, aging population, and expansion of healthcare facilities driving this market growth in this region.

Moreover, a major number of key player's presence, well-advanced healthcare infrastructure, and product launches would drive this market growth. For instance, in November 2023, BD introduced the SiteRite 9 Ultrasound System, designed to enhance clinician efficiency in placing various vascular access devices, including peripherally inserted central catheters (PICCs) and central venous catheters. This advanced system features a user-friendly 15.6-inch touchscreen and superior image quality, providing essential tools for successful catheter placement.

Also, in March 2022, Shockwave Medical, Inc. announced the global launch of the Shockwave M5+ peripheral intravascular lithotripsy (IVL) catheter following its receipt of both CE Mark and FDA clearance. This catheter, which has previously been available in a limited capacity, is specifically engineered to reduce treatment times for IVL procedures, offer alternative access options, and extend IVL therapy to patients with larger vessel sizes. The introduction of the Shockwave M5+ catheter represents a significant advancement in the treatment of severely calcified cardiovascular disease, enhancing the efficiency and effectiveness of vascular interventions.

In addition, key player's technological advancements and product approvals driving this market growth. For instance, in November 2023, BD unveiled its new PIVOTM Pro Needle-free Blood Collection Device. This innovative solution, which received 510(k) clearance from the FDA, is designed to work with integrated and long peripheral IV catheters, including BD's Nexiva Closed IV Catheter System with NearPort IV Access.

Market Segmentation

By Type

Peripheral Inserted Central Catheter

Non-tunneled Catheters

Tunneled Catheters

Implanted Ports

By Application

Drug Administration

Parenteral Nutrition

Chemotherapy

Blood Transfusion

Diagnostics & Testing

By End-User

Hospitals

Specialty Clinics

Ambulatory Surgery Centers

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

The rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the central vascular access devices market include B. Braun SE, Terumo Medical Corporation, Teleflex Incorporated, Access Vascular, Inc., BD, Cook, Medtronic, Baxter, Smith's Group plc (ICU Medical, Inc.), and AngioDynamics.

Key Developments

In May 2023, Teleflex announced the launch of two new devices aimed at improving peripherally inserted central catheter (PICC) insertion procedures and minimizing complications. The newly introduced Arrow VPS Rhythm DLX device and the NaviCurve stylet are designed to work in tandem, providing vascular access specialists with a more efficient and predictable method for PICC placement.

In June 2021, medK introduced a needle-free solution for vascular access. This innovative connection allows for safe and rapid access to fluid lines while eliminating the risk of needle stick injuries. The new device enhances safety for both healthcare professionals and patients by removing the need for traditional needle-based access methods.

Why Purchase the Report?

To visualize the global central vascular access devices market segmentation based on type, application, end-user, and region and understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the central vascular access devices market with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in excel consisting of key products of all the major players.

The global central vascular access devices market report would provide approximately 62 tables, 56 figures, and 181 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Chronic Diseases & Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Risk of Infections & Complications
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Peripheral Inserted Central Catheter*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Non-tunneled Catheters
  • 6.4. Tunneled Catheters
  • 6.5. Implanted Ports

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Drug Administration *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Parenteral Nutrition
  • 7.4. Chemotherapy
  • 7.5. Blood Transfusion
  • 7.6. Diagnostics & Testing

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Specialty Clinics
  • 8.4. Ambulatory Surgery Centers
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. B. Braun SE *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Terumo Medical Corporation
  • 11.3. Teleflex Incorporated
  • 11.4. Access Vascular, Inc.
  • 11.5. BD
  • 11.6. Cook
  • 11.7. Medtronic
  • 11.8. Baxter
  • 11.9. Smith's Group plc (ICU Medical, Inc.)
  • 11.10. AngioDynamics (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦